Volume 94 Issue 36 | p. 15 | Concentrates
Issue Date: September 12, 2016

U.S. funds work on two Zika vaccines

Department: Business
Keywords: vaccines, Zika, viruses

The Biomedical Advanced Research & Development Authority has committed to supporting two companies’ early-stage development of Zika vaccines. Japan’s Takeda Pharmaceutical will receive $20 million over 18 months to complete preclinical work and a Phase I clinical trial of its inactivated whole-virus vaccine. BARDA is also putting $8 million over four years into similar work at Moderna Therapeutics on its mRNA-based vaccine. BARDA may extend the agreements for another five to six years, putting Takeda in a position to receive up to $311 million and Moderna up to $126 million.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment